JAK2 V617F MUTATION AND PRV-1 OVEREXPRESSION: RELEVANCE IN THE DIAGNOSIS OF POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA

被引:1
|
作者
Melis, S. [1 ]
Vellinga, S. [1 ]
Zachee, P. [1 ]
Sierens, A. C. [1 ]
De Schouwer, P. J. J. C. [1 ]
机构
[1] ZNA Stuivenberg, Lab Hematol Mol Biol, B-2060 Antwerp, Belgium
关键词
JAK2 V617F mutation; PRV-1; overexpression; essential thrombocythaemia; polycythaemia vera; CHRONIC MYELOPROLIFERATIVE DISORDERS; TYROSINE KINASE JAK2; JAK2(V617F) MUTATION; EXPRESSION; SECONDARY;
D O I
10.1179/acb.2009.070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the diagnosis of potycythaemia vera and essential thrombocythaernia, two molecular markers were described in the last decade: the overexpression of the PRV-1 gene and the V617F mutation in the JAK2 gene. In this study we assess their usefulness by comparing our test results with the available clinical data. We show that in the diagnosis of polycythaemia vera the JAK2 mutation screening is crucial, while testing for the PRV-1 overexpression is redundant. On the contrary, in the diagnosis of essential thrombocythaernia (ET), both JAK2 and PRV-1 show their usefulness.
引用
收藏
页码:429 / 433
页数:5
相关论文
共 50 条
  • [31] A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F
    Acharya, A.
    Vaniawala, S.
    Parekh, H.
    Sheikh, H.
    Patel, H.
    Ali, R.
    Khan, A.
    Nagee, A.
    Kunjadia, P.
    Mukhopadhyaya, P. N.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 (04) : E30 - E33
  • [32] JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
    Li, Juan
    Spensberger, Dominik
    Ahn, Jong Sook
    Anand, Shubha
    Beer, Philip A.
    Ghevaert, Cedric
    Chen, Edwin
    Forrai, Ariel
    Scott, Linda M.
    Ferreira, Rita
    Campbell, Peter J.
    Watson, Steve P.
    Liu, Pentao
    Erber, Wendy N.
    Huntly, Brian J. P.
    Ottersbach, Katrin
    Green, Anthony R.
    BLOOD, 2010, 116 (09) : 1528 - 1538
  • [33] Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
    Basquiera, Ana L.
    Soria, Nestor W.
    Ryser, Ricardo
    Salguero, Miriam
    Moiraghi, Beatriz
    Sackmann, Federico
    Sturich, Ana G.
    Borello, Adriana
    Berretta, Adriana
    Bonafe, Miriam
    Moreno Barral, Jose
    Palazzo, Emilio D.
    Garcia, Juan J.
    HEMATOLOGY, 2009, 14 (06) : 323 - 330
  • [34] Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism
    Rodger, Marc A.
    Kekre, Natasha
    Le Gal, Gregoire
    Kahn, Susan R.
    Wells, Philip S.
    Anderson, David A.
    Chagnon, Isabelle
    Solymoss, Sussan
    Crowther, Mark
    Perrier, Arnaud
    White, Richard
    Vickars, Linda
    Ramsay, Timothy
    Betancourt, Marisol T.
    Kovacs, Michael J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (04) : 511 - 513
  • [35] No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage
    Dahabreh, Issa J.
    Jones, Amy V.
    Voulgarelis, Michael
    Giannouli, Stavroula
    Zoi, Christine
    Alafakis-Tzannatos, Christina
    Varla-Leftherioti, Marighoula
    Moutsopoulos, Haralampos M.
    Loukopoulos, Dimitris
    Fotiou, Stelios
    Cross, Nicholas C. P.
    Zoi, Katerina
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (05) : 802 - 803
  • [36] Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation
    Er, Tze-Kiong
    Lin, Sheng-Fung
    Chang, Jan-Gowth
    Hsieh, Li-Ling
    Lin, Shu-Kai
    Wang, Li-Hsuan
    Lin, Chin-Wen
    Chang, Chao-Sung
    Liu, Ta-Chih
    CLINICA CHIMICA ACTA, 2009, 408 (1-2) : 39 - 44
  • [37] Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
    Benati, Marco
    Montagnana, Martina
    Danese, Elisa
    De Matteis, Giovanna
    Veneri, Dino
    Paviati, Elisa
    Guidi, Gian Cesare
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (07) : 1005 - 1011
  • [38] The prevalence of the JAK2 V617F Exon 14 mutation in Sudanese patients with Myelo Proliferative Neoplasms (MPNs)
    Yasin, Elrashed B.
    Kordofani, Anwaar A. Y.
    Elamin, Bahaeldin K.
    Dallol, A.
    BIOSCIENCE RESEARCH, 2019, 16 (03): : 2423 - 2429
  • [39] Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting
    Lin, Chien-Yu
    Ho, Cheng-Mao
    Tamamyan, Gevorg
    Yang, Shu-Fen
    Peng, Ching-Tien
    Chang, Jan-Gowth
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2016, 30 (06) : 838 - 844
  • [40] Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation
    Meyer, Thomas
    Ruppert, Volker
    Goerg, Christian
    Neubauer, Andreas
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (01) : 117 - 120